Related Experiment Video
Updated: May 26, 2026
05:23
Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload
Published on: March 14, 2017
Management of essential thrombocythemia
1Hematology Department, Hospital Clinic, University of Barcelona, Barcelona, Spain.
Hematology. American Society of Hematology. Education Program
|December 14, 2011
Summary
Essential thrombocythemia (ET) is a myeloproliferative neoplasm causing high platelet counts. Treatment focuses on preventing thrombosis and bleeding, with hydroxyurea as a primary therapy for high-risk patients.
Area of Science:
- Hematology
- Oncology
- Internal Medicine
Background:
- Essential thrombocythemia (ET) is a Philadelphia chromosome-negative myeloproliferative neoplasm (MPN).
- Characterized by thrombocytosis and bone marrow megakaryocytic hyperplasia.
- JAK2 V617F mutation present in 50%-60% of patients.
Purpose of the Study:
- To outline current treatment strategies for Essential thrombocythemia.
- To emphasize the importance of preventing vascular complications and disease transformation.
- To discuss risk stratification for thrombosis and bleeding.
Main Methods:
- Review of existing literature and clinical guidelines for ET management.
- Risk assessment based on age, thrombosis history, and platelet count.
- Description of first-line and second-line therapeutic options.
Main Results:
- Low-risk ET managed with low-dose aspirin.
- High-risk ET treated with cytoreductive therapy (hydroxyurea first-line, anagrelide second-line).
- IFN-α reserved for young patients or pregnant women; JAK inhibitors under investigation.
Conclusions:
- ET treatment aims to prevent thrombosis and bleeding without increasing leukemia risk.
- Management includes risk stratification and appropriate therapy selection.
- Control of cardiovascular risk factors is crucial for all ET patients.
Related Concept Videos
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
01:30Venous Thrombosis IV: Nursing Management
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
01:14Myocarditis III: Medical Management
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
01:21Rheumatic Heart Disease III: Medical Management
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
01:22Myocarditis IV: Nursing Management
Myocarditis is an inflammatory condition of the myocardium requiring meticulous nursing management for optimal patient outcomes. Effective management begins with a thorough assessment of the patient's medical history, paying close attention to past infections, autoimmune disorders, travel history, and exposure to toxins or drugs. Recent viral infections and systemic diseases are particularly relevant due to their potential role in triggering myocarditis.Physical Examination and MonitoringThe...